Benjamin Carr
Psychiatry · Gadsden, ALNPI 1316999287
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 1,112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,112 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$2K
- Alkermes, Inc.$1K
- Tris Pharma Inc$1K
- plus $7K from 26 others
What the payments were for
- Food & beverage$17,905100%
- Education$490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 135 | $2,481 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 136 | $2,083 |
| Otsuka America Pharmaceutical, Inc. | 111 | $1,800 |
| AbbVie(2 entities) | 128 | $1,671 |
| Alkermes, Inc. | 79 | $1,381 |
| Tris Pharma Inc | 86 | $1,234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 66 | $1,050 |
| Ironshore Pharmaceuticals Inc. | 78 | $971 |
| Lundbeck LLC | 58 | $895 |
| Corium, LLC | 54 | $781 |
| Galt Pharmaceuticals, LLC | 1 | $771 |
| Axsome Therapeutics, Inc. | 48 | $670 |
| Johnson & Johnson | 21 | $368 |
| Neos Therapeutics, LP | 16 | $252 |
| Idorsia Pharmaceuticals US Inc | 11 | $164 |
| Collegium Pharmaceutical, Inc. | 12 | $153 |
| Almatica Pharma LLC | 9 | $151 |
| Adlon Therapeutics L.p. | 9 | $134 |
| E.r. Squibb & Sons, L.L.C. | 7 | $120 |
| Teva Pharmaceuticals USA, Inc. | 6 | $112 |
| Eisai Inc. | 7 | $109 |
| Arbor Pharmaceuticals, Inc. | 7 | $107 |
| Vanda Pharmaceuticals Inc. | 4 | $104 |
| Vertical Pharmaceuticals, LLC | 5 | $84 |
| Shire North American Group Inc | 6 | $81 |
| Merck | 4 | $77 |
| Noven Therapeutics, LLC | 3 | $66 |
| Noven Pharmaceuticals, Inc. | 1 | $20 |
| Neuronetics, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Bausch Health US, LLC | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orphengesic Forte$771
- QELBREE$169
How this compares
$17,954 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 47 | $68,196 |
| VraylarCariprazine Hcl | 17 | $35,943 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $30,437 |
| TrintellixVortioxetine Hydrobromide | 26 | $19,409 |
| CaplytaLumateperone Tosylate | 11 | $17,351 |
| Aripiprazole | 52 | $8,944 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 240 | $7,920 |
| Clonazepam | 423 | $3,979 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 62 | $3,926 |
| Lisdexamfetamine Dimesylate | 18 | $3,213 |
| Vilazodone Hcl | 11 | $2,893 |
| Duloxetine Hcl | 63 | $2,869 |
| Bupropion XlBupropion Hcl | 31 | $2,552 |
| Trazodone Hcl | 101 | $2,287 |
| Divalproex Sodium ErDivalproex Sodium | 36 | $2,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,800 | $68,19647 claims |
| AbbVieVraylar | $1,671 | $35,94317 claims |
| Alkermes, Inc.Lybalvi | $1,381 | $30,43716 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,050 | $19,40926 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,083 | $17,35111 claims |
| Almatica Pharma LLCSertraline Hcl | $151 | $59332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Gadsden
- Huma KhusroGadsden$6K
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Scariya KumaramangalamHuntsville$440K
- Mark HaygoodMobile$348K
- Lori DavisTuscaloosa$161K
- Bradley SadlerMobile$124K
- Brandi Rudolph BollingJasper$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.